653 related articles for article (PubMed ID: 29407764)
1. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
2. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
3. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
Zádor F; Kocsis D; Borsodi A; Benyhe S
Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
[TBL] [Abstract][Full Text] [Related]
4. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
[TBL] [Abstract][Full Text] [Related]
6. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Ahn KH; Mahmoud MM; Kendall DA
J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes.
Cinar R; Freund TF; Katona I; Mackie K; Szucs M
Neurochem Int; 2008 Jun; 52(8):1402-9. PubMed ID: 18407377
[TBL] [Abstract][Full Text] [Related]
12. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
13. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Cinar R; Szücs M
J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
[TBL] [Abstract][Full Text] [Related]
14. Interactive effects of AM251 and baclofen on synaptic plasticity in the rat dentate gyrus.
Nazari M; Komaki A; Salehi I; Sarihi A; Shahidi S; Komaki H; Ganji A
Brain Res; 2016 Nov; 1651():53-60. PubMed ID: 27663967
[TBL] [Abstract][Full Text] [Related]
15. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
16. COR758, a negative allosteric modulator of GABA
Porcu A; Mostallino R; Serra V; Melis M; Sogos V; Beggiato S; Ferraro L; Manetti F; Gianibbi B; Bettler B; Corelli F; Mugnaini C; Castelli MP
Neuropharmacology; 2021 May; 189():108537. PubMed ID: 33798546
[TBL] [Abstract][Full Text] [Related]
17. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.
Jergas B; Schulte K; Bindila L; Lutz B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):621-8. PubMed ID: 24853577
[TBL] [Abstract][Full Text] [Related]
18. Decreased GABAA and GABAB receptor functional activity in cannabinoid CB1 receptor knockout mice.
Urigüen L; García-Gutiérrez MS; Manzanares J
J Psychopharmacol; 2011 Jan; 25(1):105-10. PubMed ID: 20142297
[TBL] [Abstract][Full Text] [Related]
19. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.
Fay JF; Farrens DL
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912
[TBL] [Abstract][Full Text] [Related]
20. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
Dennis I; Whalley BJ; Stephens GJ
Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
